About Neogenix Oncology
Neogenix Oncology is a company based in Great Neck (United States) founded in 2003 was acquired by Precision Biologics in July 2012.. Neogenix Oncology has raised $15.85 million across 2 funding rounds from investors including Precision Biologics.
- Headquarter Great Neck, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$15.85 M (USD)
in 2 rounds
-
Latest Funding Round
$846.23 K (USD), Series B
Oct 08, 2010
- Investors
-
Employee Count
Employee Count
-
Acquired by
Precision Biologics
(Jul 23, 2012)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Neogenix Oncology
Neogenix Oncology has successfully raised a total of $15.85M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $846.23 thousand completed in October 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $846,225
-
First Round
First Round
(13 May 2009)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2010 | Amount | Series B - Neogenix Oncology | Valuation |
investors |
|
| May, 2009 | Amount | Series B - Neogenix Oncology | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Neogenix Oncology
Neogenix Oncology has secured backing from 1 investor. Prominent investors backing the company include Precision Biologics. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Precision Biologics is focused on developing innovative cancer therapies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Neogenix Oncology
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Neogenix Oncology
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Neogenix Oncology Comparisons
Competitors of Neogenix Oncology
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Neogenix Oncology
When was Neogenix Oncology founded?
Neogenix Oncology was founded in 2003 and raised its 1st funding round 6 years after it was founded.
Where is Neogenix Oncology located?
Neogenix Oncology is headquartered in Great Neck, United States. It is registered at Great Neck, New York, United States.
Is Neogenix Oncology a funded company?
Neogenix Oncology is a funded company, having raised a total of $15.85M across 2 funding rounds to date. The company's 1st funding round was a Series B of $15M, raised on May 13, 2009.
What does Neogenix Oncology do?
Neogenix Oncology was a clinical stage company, developing antibodies for the treatment of pancreatic, colon, lung, prostate,etc.. The lead candidate, NEO-101 (Ensituximab) is a monoclonal antibody (mAb) was in Phase IIa trials for colorectal and pancreatic cancer. Other candidates, NEO-201 and NEO-301, which were in preclinical stage for cancer indication. The was acquired by Precision Biologics in Sep 2012.
Who are Neogenix Oncology's investors?
Neogenix Oncology has 1 investor. Key investors include Precision Biologics.